Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center

Journal of Thoracic Oncology

Volumn 2, Issue 10, 2007, Pages 957-965

  Flores, Raja M ^a   Zakowski, Maureen ^a   Venkatraman, Ennapadam ^a   Krug, Lee ^a   Rosenzweig, Kenneth ^a   Dycoco, Joseph ^a   Lee, Catherine ^a   Yeoh, Cindy ^a   Bains, Manjit ^a   Rusch, Valerie ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Decortication; Extrapleural pneumonectomy; Malignant mesothelioma; Pleurectomy

Indexed keywords

ASBESTOS;

ADULT; AGED; ARTICLE; ASBESTOSIS; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; DECORTICATION; DIAGNOSTIC ACCURACY; FEMALE; HAZARD ASSESSMENT; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LOG RANK TEST; LUNG BIOPSY; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MEDICAL ASSESSMENT; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PLEURECTOMY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REFERENCE DATABASE; SMOKING; STATISTICAL SIGNIFICANCE; SURGICAL MORTALITY; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; TERTIARY HEALTH CARE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OUTCOME ASSESSMENT (HEALTH CARE); PLEURAL NEOPLASMS; PROGNOSIS; REMISSION INDUCTION; SMOKING; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34848873146     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31815608d9     Document Type: Article

References (16)

1. Ruffie P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 322 patients. J Clin Oncol 1989;7:1157-1168.
2. Alberts AS, Falkson G, Goedhals L, et al. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988;6:527-535.
3. Butchart E, Ashcroft T, Barnsley W, et al. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: experience with 29 patients. Thorax 1976;31:15-24.
4. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative longterm survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-65.
5. Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 1999;68:1799-1804.
6. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998;113:723-731.
7. Aziz T, Jilaihawi A, Prakash D. The management of malignant pleural mesothelioma; single centre experience in 10 years. Eur J Cardiothorac Surg 2002;22:298-305.
8. Lee TT, Everett DL, Shu HG, et al. Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc 2002;124:1183-1189.
9. Maggi G, Casadio C, Cianci R, Rena O, Ruffini E. Trimodality management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 2001;19:346-350.
10. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644.
11. AJCC Cancer Staging, 6th Edition. New York: Springer, 2001.
12. Yajnik S, Rosenzweig KE, Mychalczak B, et al. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2003;56:1319-1326.
13. Gupta V, Mychalczak B, Krug L, et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2005;63:1045-1052.
14. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;122:788-795.
15. Flores RM, Akhurst T, Gonen M, Larson SM, Rusch VW. Positron emission tomography defines metastatic disease but no locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2003;126:11-16.
16. Flores RM, Akhurst T, Gonen M, et al. Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2006;132:763-768.